Arcus Biosciences officer exercises 1,900 options, sells matching shares

Arcus Biosciences Chief Accounting Officer reports option exercise and share sale.

Rhea-AI Filing Summary

Arcus Biosciences Chief Accounting Officer reports option exercise and share sale. On 11/26/2025, the officer exercised a stock option to acquire 1,900 shares of Arcus Biosciences common stock at $13.33 per share and on the same date sold 1,900 shares at $26 per share under a Rule 10b5-1 trading plan. After these transactions, the officer directly beneficially owned 27,363 shares of common stock and 9,500 stock options with a $13.33 exercise price, which are scheduled to become exercisable in 48 equal monthly installments after January 1, 2025 and expire on January 22, 2035.

Insider Trade Summary

Exercise and Sale: 1,900 shares ($24K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Azoy Alexander

Role Chief Accounting Officer

Sold 1,900 shs ($49K)

Approx. gross sale proceeds $49K

Approx. exercise cost $25K

Approx. pre-tax spread $24K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	1,900	$0.00	$0.00
Exercise	Common Stock	1,900	$13.33	$25K
Sale	Common Stock	1,900	$26.00	$49K

Holdings After Transaction: Stock Option (right to buy) — 9,500 contracts (Direct); Common Stock — 27,363 shares (Direct)

Footnotes (2)

1. F1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
2. F2. The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arcus Biosciences (RCUS) report in this Form 4?

The Chief Accounting Officer exercised a stock option for 1,900 shares of Arcus Biosciences common stock at $13.33 per share and sold 1,900 shares at $26 per share on 11/26/2025.

Who is the reporting person in this Arcus Biosciences (RCUS) Form 4 and what is their role?

The reporting person is an officer of Arcus Biosciences, serving as the company’s Chief Accounting Officer.

How many Arcus Biosciences (RCUS) shares does the officer own after the reported transactions?

Following the reported transactions, the officer directly beneficially owned 27,363 shares of Arcus Biosciences common stock.

What stock options does the Arcus Biosciences (RCUS) officer still hold?

After the transactions, the officer held 9,500 stock options with an exercise price of $13.33 per share, scheduled to vest in 48 equal monthly installments after January 1, 2025 and expiring on January 22, 2035.

Was the Arcus Biosciences (RCUS) insider trade made under a Rule 10b5-1 plan?

Yes. The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

What is the significance of the transaction codes M and S in this Arcus Biosciences Form 4?

Transaction code M indicates the exercise of a stock option, and transaction code S indicates a sale of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/01/2025 - 06:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azoy Alexander

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/26/2025		M		1,900(1)	A	$13.33	29,263	D
Common Stock	11/26/2025		S		1,900(1)	D	$26	27,363	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.33	11/26/2025		M			1,900(1)	(2)	01/22/2035	Common Stock	1,900	$0	9,500	D

Explanation of Responses:

1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	12/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.